MA29342B1 - Nouvelle composition - Google Patents

Nouvelle composition

Info

Publication number
MA29342B1
MA29342B1 MA30241A MA30241A MA29342B1 MA 29342 B1 MA29342 B1 MA 29342B1 MA 30241 A MA30241 A MA 30241A MA 30241 A MA30241 A MA 30241A MA 29342 B1 MA29342 B1 MA 29342B1
Authority
MA
Morocco
Prior art keywords
influenza
pandemic
push
preparation
immunization
Prior art date
Application number
MA30241A
Other languages
English (en)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36441219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29342(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0505989A external-priority patent/GB0505989D0/en
Priority claimed from GB0505998A external-priority patent/GB0505998D0/en
Priority claimed from GB0506001A external-priority patent/GB0506001D0/en
Priority claimed from GB0506000A external-priority patent/GB0506000D0/en
Priority claimed from GB0506004A external-priority patent/GB0506004D0/en
Priority claimed from GB0510589A external-priority patent/GB0510589D0/en
Priority claimed from GB0510596A external-priority patent/GB0510596D0/en
Priority claimed from GB0510598A external-priority patent/GB0510598D0/en
Priority claimed from GB0510591A external-priority patent/GB0510591D0/en
Priority claimed from GB0510593A external-priority patent/GB0510593D0/en
Priority claimed from GB0603789A external-priority patent/GB0603789D0/en
Priority claimed from GB0603788A external-priority patent/GB0603788D0/en
Priority claimed from GB0603790A external-priority patent/GB0603790D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29342B1 publication Critical patent/MA29342B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMULATIONS DE VACCIN CONTRE LA GRIPPE ET DES RÉGIMES DE VACCINATION POUR L¿IMMUNISATION CONTRE LA MALADIE DE LA GRIPPE, LEUR UTILISATION EN MÉDECINE, EN PARTICULIER LEUR UTILISATION DANS L¿AUGMENTATION DES RÉPONSES IMMUNES À DIVERS ANTIGÈNES, ET DES PROCÉDÉS DE PRÉPARATION. EN PARTICULIER, L¿INVENTION CONCERNE DES COMPOSITIONS IMMUNOGÈNES MULTIVALENTES DE GRIPPE COMPRENANT UN ANTIGÈNE DE LA GRIPPE OU SA PRÉPARATION ANTIGÉNIQUE À PARTIR D¿AU MOINS DEUX SOUCHES DE VIRUS DE LA GRIPPE, AU MOINS UNE SOUCHE ÉTANT ASSOCIÉE AVEC UNE POUSSÉE PANDÉMIQUE OU POUVANT ÊTRE ASSOCIÉE AVEC UNE POUSSÉE PANDÉMIQUE, EN COMBINAISON AVEC UN ADJUVANT DE TYPE ÉMULSION HUILE DANS L¿EAU.
MA30241A 2005-03-23 2007-09-24 Nouvelle composition MA29342B1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0505998A GB0505998D0 (en) 2005-03-23 2005-03-23 Novel compositions
GB0506001A GB0506001D0 (en) 2005-03-23 2005-03-23 Novel use
GB0506000A GB0506000D0 (en) 2005-03-23 2005-03-23 Novel use
GB0506004A GB0506004D0 (en) 2005-03-23 2005-03-23 Compositions
GB0505989A GB0505989D0 (en) 2005-03-23 2005-03-23 Compositions
GB0510596A GB0510596D0 (en) 2005-05-24 2005-05-24 Composition
GB0510589A GB0510589D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510598A GB0510598D0 (en) 2005-05-24 2005-05-24 Composition
GB0510591A GB0510591D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510593A GB0510593D0 (en) 2005-05-24 2005-05-24 Novel compositions
GB0603789A GB0603789D0 (en) 2006-02-24 2006-02-24 Novel use
GB0603788A GB0603788D0 (en) 2006-02-24 2006-02-24 Novel composition
GB0603790A GB0603790D0 (en) 2006-02-24 2006-02-24 Composition

Publications (1)

Publication Number Publication Date
MA29342B1 true MA29342B1 (fr) 2008-03-03

Family

ID=36441219

Family Applications (3)

Application Number Title Priority Date Filing Date
MA30238A MA30298B1 (fr) 2005-03-23 2007-09-24 Composition
MA30240A MA29715B1 (fr) 2005-03-23 2007-09-24 Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b
MA30241A MA29342B1 (fr) 2005-03-23 2007-09-24 Nouvelle composition

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA30238A MA30298B1 (fr) 2005-03-23 2007-09-24 Composition
MA30240A MA29715B1 (fr) 2005-03-23 2007-09-24 Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b

Country Status (24)

Country Link
US (5) US20080181911A1 (fr)
EP (4) EP2397153A1 (fr)
JP (4) JP5869744B2 (fr)
KR (5) KR20070116651A (fr)
AR (3) AR054020A1 (fr)
AU (3) AU2006226543B2 (fr)
CA (3) CA2602456A1 (fr)
CY (1) CY1117874T1 (fr)
DK (1) DK1861120T3 (fr)
EA (3) EA011393B1 (fr)
ES (1) ES2585810T3 (fr)
HR (1) HRP20160816T1 (fr)
HU (1) HUE027837T2 (fr)
IL (3) IL185901A0 (fr)
MA (3) MA30298B1 (fr)
MX (3) MX2007011756A (fr)
NO (3) NO20074638L (fr)
NZ (2) NZ561822A (fr)
PE (3) PE20061300A1 (fr)
PL (1) PL1861120T3 (fr)
PT (1) PT1861120T (fr)
SI (1) SI1861120T1 (fr)
TW (3) TW200722101A (fr)
WO (3) WO2006100109A1 (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221761B1 (en) * 1999-02-26 2012-07-17 Novartis Ag Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
JP5869744B2 (ja) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1951300T3 (pl) * 2005-11-04 2012-03-30 Novartis Ag Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
US20110180430A1 (en) * 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
CA2628152C (fr) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
EA014028B1 (ru) * 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2476432B1 (fr) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation
EP2004226A1 (fr) * 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Stockage de vaccins antigrippaux sans refrigeration
CN101500603A (zh) * 2006-06-15 2009-08-05 诺华有限公司 节省佐剂的多剂量流感疫苗接种方案
CA2583555C (fr) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Vaccin contre la grippe
KR101696727B1 (ko) * 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
PL2422810T3 (pl) * 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
EP2086582B1 (fr) * 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccin comprenant une emulsion adjuvante huile en l'eau
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP1923070A1 (fr) * 2006-11-15 2008-05-21 Intervet International BV Vaccin pour vacciner un félin contre le virus influenza
NZ577405A (en) * 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP1938835A1 (fr) * 2006-12-29 2008-07-02 Pevion Biotech AG Agent immunostimulant non spécifique
NZ710459A (en) * 2007-02-23 2016-06-24 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
SG185294A1 (en) * 2007-10-12 2012-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
JP5701058B2 (ja) * 2007-10-19 2015-04-15 ノバルティス アーゲー 髄膜炎菌ワクチン処方物
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227251A1 (fr) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Composition contre la grippe
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
TWI376385B (en) * 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
EP2268309B1 (fr) * 2008-03-18 2015-01-21 Novartis AG Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US9421251B2 (en) 2008-06-25 2016-08-23 Novartis Ag Rapid responses to delayed booster immunisations
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
TWI409275B (zh) * 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
EP2289575B1 (fr) * 2009-08-06 2017-07-05 Biotronik VI Patent AG Implant médical contenant une substance anti-oxydante
IN2012DN00781A (fr) * 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
EP2308506A1 (fr) * 2009-10-02 2011-04-13 Mucosis B.V. Formulations de vaccin intranasal avec adjuvants
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
SI2380558T2 (sl) * 2009-12-03 2019-11-29 Novartis Ag Izdelava emulzije z razmestitvijo interakcijske in protitlačne komore za mikrofluidizacijo
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
AU2013202690B2 (en) * 2009-12-03 2016-02-11 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2356983B1 (fr) 2009-12-03 2013-02-20 Novartis AG Circulation de composants pendant l'homogénéisation d'émulsions
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
NZ599881A (en) * 2009-12-03 2014-01-31 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
KR20120107121A (ko) * 2009-12-22 2012-09-28 사노피 파스퇴르 리미티드 면역원성 조성물
AU2011203740B2 (en) * 2010-01-06 2014-11-13 Vaxinnate Corporation Methods and compositions for providing protective immunity in the elderly
WO2011088451A1 (fr) * 2010-01-15 2011-07-21 Novavax, Inc. Utilisations de particules de type virus de la grippe (vlps) pour la caractérisation de l'activité neuraminidase et hémagglutinine
RU2527688C2 (ru) * 2010-02-27 2014-09-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) * 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012116714A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des patients âgés
EP3566715A1 (fr) * 2012-12-28 2019-11-13 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Composition de vaccin contre la grippe nasale
EP2801372A3 (fr) * 2013-05-10 2015-02-18 Novartis AG Éviter le risque de narcolepsie dans des vaccins contre la grippe
US10080792B2 (en) * 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
AU2015323334B2 (en) 2014-09-26 2021-02-25 Seqirus UK Limited Vaccination of immunocompromised subjects
WO2019108928A1 (fr) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Système d'administration de vaccin contre le virus de la grippe piégé par des nanoparticules mucoadhésives
WO2020160080A1 (fr) 2019-01-30 2020-08-06 Glaxosmithkline Llc Mélanges huile/tensioactif pour auto-émulsification
WO2021123117A1 (fr) * 2019-12-20 2021-06-24 Fresenius Kabi Austria Gmbh Procédé de production d'émulsions huile dans l'eau
RU2741003C1 (ru) * 2020-03-27 2021-01-22 Евгений Дмитриевич Некрасов Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов
EP4171629A1 (fr) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
CA3190375A1 (fr) 2020-08-24 2022-03-03 Natalie ANOSOVA Vaccins contre la covid-19 avec des adjuvants d'emulsion de squalene contenant du tocopherol
MX2023002339A (es) 2020-08-24 2023-03-22 Sanofi Pasteur Inc Vacunas contra infecciones por sars-cov-2.
KR102270165B1 (ko) 2020-10-22 2021-06-28 한국화학연구원 세정제 조성물
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2023274860A1 (fr) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Nouveaux antigènes de la grippe
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023061993A1 (fr) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095974A (en) * 1961-10-27 1963-07-02 Anthony R Perini Collapsible book rack
US4047869A (en) * 1973-02-23 1977-09-13 Mulvany Jr R F Apparatus for forming plastic articles
FR2333610A1 (fr) * 1975-12-03 1977-07-01 Zhdanovsky Z Tyazhelogo Mash Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
CA1283827C (fr) 1986-12-18 1991-05-07 Giorgio Cirelli Dispositif pour l'injection de formules liquides
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
EP0382271B1 (fr) * 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols comme adjuvants de vaccins
US5092235A (en) 1989-05-24 1992-03-03 Tektronix, Inc. Pressure fixing and developing apparatus
CA2017507C (fr) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1991013261A1 (fr) 1990-03-02 1991-09-05 Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov Systeme numerique d'entrainement asservi
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
CA2156525A1 (fr) 1993-02-19 1994-09-01 Susan Dillon Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DK0729473T3 (da) 1993-11-17 2000-10-30 Deutsche Om Arzneimittel Gmbh Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3836874B2 (ja) 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
WO1995024176A1 (fr) 1994-03-07 1995-09-14 Bioject, Inc. Dispositif de remplissage d'ampoule
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
WO1999056776A2 (fr) 1998-05-07 1999-11-11 Corixa Corporation Composition d'adjuvant et procedes d'utilisation de celle-ci
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1574210B1 (fr) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions à macromolécules adsorbées
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
PL211762B1 (pl) 2000-01-31 2012-06-29 Smithkline Beecham Biolog Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
EP1201250A1 (fr) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
AU2003224819A1 (en) * 2002-04-01 2003-10-20 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
JP5600375B2 (ja) * 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
JP5869744B2 (ja) * 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
PL2422810T3 (pl) * 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2227251A1 (fr) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Composition contre la grippe

Also Published As

Publication number Publication date
CA2601022A1 (fr) 2006-09-28
EA011393B1 (ru) 2009-02-27
NO20074635L (no) 2007-12-19
AU2006226543A1 (en) 2006-09-28
WO2006100111A1 (fr) 2006-09-28
IL185901A0 (en) 2008-01-06
CY1117874T1 (el) 2017-05-17
MX2007011775A (es) 2008-03-11
KR20160064249A (ko) 2016-06-07
JP5770414B2 (ja) 2015-08-26
NZ561823A (en) 2010-04-30
ES2585810T3 (es) 2016-10-10
DK1861120T3 (en) 2016-07-25
US20140363474A1 (en) 2014-12-11
PT1861120T (pt) 2016-08-18
TW200700079A (en) 2007-01-01
TW200700078A (en) 2007-01-01
AU2006226458B2 (en) 2012-08-30
WO2006100109A1 (fr) 2006-09-28
US9730999B2 (en) 2017-08-15
NZ561822A (en) 2010-04-30
KR20140004815A (ko) 2014-01-13
AU2006226459A1 (en) 2006-09-28
JP2008534465A (ja) 2008-08-28
IL185897A0 (en) 2008-01-06
PE20061300A1 (es) 2006-12-23
EP2397153A1 (fr) 2011-12-21
IL185897A (en) 2015-11-30
US20080171063A1 (en) 2008-07-17
KR101916787B1 (ko) 2019-01-24
US20090081253A1 (en) 2009-03-26
JP2008534467A (ja) 2008-08-28
JP5869744B2 (ja) 2016-02-24
MA29715B1 (fr) 2008-09-01
EP1861120A1 (fr) 2007-12-05
MA30298B1 (fr) 2009-04-01
EA011419B1 (ru) 2009-02-27
KR20070116650A (ko) 2007-12-10
SI1861120T1 (sl) 2016-09-30
NO20074930L (no) 2007-12-07
AU2006226458A1 (en) 2006-09-28
CA2603180A1 (fr) 2006-09-28
AR052625A1 (es) 2007-03-21
AR053833A1 (es) 2007-05-23
PE20061428A1 (es) 2007-01-16
US20080181911A1 (en) 2008-07-31
AR054020A1 (es) 2007-05-30
EA200701786A1 (ru) 2008-04-28
IL185906A0 (en) 2008-01-06
US20110287054A1 (en) 2011-11-24
CA2603180C (fr) 2015-10-13
WO2006100110A1 (fr) 2006-09-28
MX2007011756A (es) 2008-03-11
MX2007011748A (es) 2008-03-11
KR20070116651A (ko) 2007-12-10
CA2602456A1 (fr) 2006-09-28
JP2014129359A (ja) 2014-07-10
JP2008534466A (ja) 2008-08-28
EP1861122A1 (fr) 2007-12-05
KR20070116652A (ko) 2007-12-10
EA200701787A1 (ru) 2008-08-29
HUE027837T2 (en) 2016-11-28
CA2601022C (fr) 2023-03-07
EP1863529A1 (fr) 2007-12-12
EP1861120B1 (fr) 2016-05-25
PE20061387A1 (es) 2007-01-19
NO20074638L (no) 2007-12-19
PL1861120T3 (pl) 2016-11-30
AU2006226543B2 (en) 2011-10-06
EA200701785A1 (ru) 2008-04-28
TW200722101A (en) 2007-06-16
HRP20160816T1 (hr) 2016-08-12

Similar Documents

Publication Publication Date Title
MA29342B1 (fr) Nouvelle composition
MA30624B1 (fr) Vaccin anti-grippal
MA30866B1 (fr) Vaccin
RU2434638C2 (ru) Вакцина альфа токсоида с.perfringens
MA31381B1 (fr) Vaccin contre la grippe a emulsion huile dans l'eau
CO6270339A2 (es) Formulaciones de vacuna meningococica
MA29601B1 (fr) Vaccin antipaludeen
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
WO2009076158A8 (fr) Compositions utilisées pour induire des réponses immunitaires
MA29244B1 (fr) Compositions permettant d'immuniser contre une mycobacterie
MA29978B1 (fr) Antigenes chimeriques et vaccins
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
MA37432A1 (fr) Virus modifié de la maladie de marek, et vaccins préparés à partir de celui-ci
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
SG160386A1 (en) Novel composition
MA56283A1 (fr) Compositions immunogènes contre des maladies entériques et leurs procédés de préparation
CY1115921T1 (el) Εμβολιο γριπης
Lawrence Meningococcal vaccine group-c conjugate
UY29429A1 (es) Composición inmunogénica que contiene virus de la gripe o preparación antígena del mismo, sus usos y procedimientos de preparación.
Farjah et al. PROTECTION AGAINST P. AERUGINOSA WITH A SYNTHETIC PEPTIDE DERIVED FROM OMP F CONJUGATED TO OUTER MEMBRANE VESICLE (OMV) OF NEISSERIA MENINGITIDIS
Holvast et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent
FR3043558B1 (fr) Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
TH72570B (th) อิมัลชันของน้ำมันในน้ำชนิดผ่านการไมโครฟลูอิดไดซ์ และองค์ประกอบของวัคซีน
UA91701C2 (ru) Мультивалентная иммуногенная композиция против гриппа, которая включает антиген вируса гриппа и адъювант на основе эмульсии масла-в-воде